ibm-research/biomed.omics.bl.sm.ma-ted-458m.protein_solubility

The ibm/biomed.omics.bl.sm.ma-ted-458m model is a biomedical foundation model trained on over 2 billion biological samples across multiple modalities, including proteins, small molecules, and single-cell gene data. Designed for robust performance, it achieves state-of-the-art results over a variety…

Accurate prediction of drug-target binding affinity is essential in the early stages of drug discovery. This is an example of finetuning ibm/biomed.omics.bl.sm-ted-400 the task. Prediction of binding affinities using pKd, the negative logarithm of the dissociation constant, which reflects the…

Drugs targeting the central nervous system must meet stringent criteria for both efficacy and safety, including their ability to penetrate the blood-brain barrier (BBB). This model predicts the likelihood of small-molecule drugs crossing the BBB, a critical factor in CNS drug development.

Drugs must satisfy stringent criteria for both efficacy and safety. This model predicts the likelihood of failure in clinical toxicity trials for small-molecule drugs, represented using SMILES (Simplified Molecular Input Line Entry System) strings.

Drugs must satisfy stringent criteria for both efficacy and safety. This model predicts the likelihood of FDA approval for small-molecule drugs, represented using SMILES (Simplified Molecular Input Line Entry System) strings.

T-cell receptor (TCR) binding to immunogenic peptides (epitopes) presented by major histocompatibility complex (MHC) molecules is a critical mechanism in the adaptive immune system, essential for antigen recognition and triggering immune responses.